221 related articles for article (PubMed ID: 24037637)
1. Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?
Godinas L; Guignabert C; Seferian A; Perros F; Bergot E; Sibille Y; Humbert M; Montani D
Semin Respir Crit Care Med; 2013 Oct; 34(5):714-24. PubMed ID: 24037637
[TBL] [Abstract][Full Text] [Related]
2. Role of Src tyrosine kinases in experimental pulmonary hypertension.
Pullamsetti SS; Berghausen EM; Dabral S; Tretyn A; Butrous E; Savai R; Butrous G; Dahal BK; Brandes RP; Ghofrani HA; Weissmann N; Grimminger F; Seeger W; Rosenkranz S; Schermuly RT
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1354-65. PubMed ID: 22516066
[TBL] [Abstract][Full Text] [Related]
3. A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents.
Tu L; De Man FS; Girerd B; Huertas A; Chaumais MC; Lecerf F; François C; Perros F; Dorfmüller P; Fadel E; Montani D; Eddahibi S; Humbert M; Guignabert C
Am J Respir Crit Care Med; 2012 Oct; 186(7):666-76. PubMed ID: 22798315
[TBL] [Abstract][Full Text] [Related]
4. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
[TBL] [Abstract][Full Text] [Related]
5. The role of imatinib in the treatment of pulmonary hypertension.
Mucke H
Drugs Today (Barc); 2013 Mar; 49(3):203-11. PubMed ID: 23527324
[TBL] [Abstract][Full Text] [Related]
6. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
Beyer C; Distler JH; Distler O
Swiss Med Wkly; 2010; 140():w13050. PubMed ID: 20419513
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension.
Hatano M; Yao A; Shiga T; Kinugawa K; Hirata Y; Nagai R
Int Heart J; 2010 Jul; 51(4):272-6. PubMed ID: 20716845
[TBL] [Abstract][Full Text] [Related]
8. [Inhibitors for ABL, KIT and PDGFR tyrosine kinases--imatinib, nitotinib, and dasatinib].
Nishida T; Tsukazaki K
Nihon Rinsho; 2015 Feb; 73 Suppl 2():250-5. PubMed ID: 25831762
[No Abstract] [Full Text] [Related]
9. Imatinib mesylate for the treatment of pulmonary arterial hypertension.
ten Freyhaus H; Dumitrescu D; Berghausen E; Vantler M; Caglayan E; Rosenkranz S
Expert Opin Investig Drugs; 2012 Jan; 21(1):119-34. PubMed ID: 22074410
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats.
Abe K; Toba M; Alzoubi A; Koubsky K; Ito M; Ota H; Gairhe S; Gerthoffer WT; Fagan KA; McMurtry IF; Oka M
Am J Respir Cell Mol Biol; 2011 Oct; 45(4):804-8. PubMed ID: 21378262
[TBL] [Abstract][Full Text] [Related]
11. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.
Perros F; Montani D; Dorfmüller P; Durand-Gasselin I; Tcherakian C; Le Pavec J; Mazmanian M; Fadel E; Mussot S; Mercier O; Hervé P; Emilie D; Eddahibi S; Simonneau G; Souza R; Humbert M
Am J Respir Crit Care Med; 2008 Jul; 178(1):81-8. PubMed ID: 18420966
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments.
Zhao L; Ashek A; Wang L; Fang W; Dabral S; Dubois O; Cupitt J; Pullamsetti SS; Cotroneo E; Jones H; Tomasi G; Nguyen QD; Aboagye EO; El-Bahrawy MA; Barnes G; Howard LS; Gibbs JS; Gsell W; He JG; Wilkins MR
Circulation; 2013 Sep; 128(11):1214-24. PubMed ID: 23900048
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo evaluation of dasatinib and imatinib on physiological parameters of pulmonary arterial hypertension.
Baumgart B; Guha M; Hennan J; Li J; Woicke J; Simic D; Graziano M; Wallis N; Sanderson T; Bunch RT
Cancer Chemother Pharmacol; 2017 Apr; 79(4):711-723. PubMed ID: 28283735
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary arterial hypertension in patients treated by dasatinib.
Montani D; Bergot E; Günther S; Savale L; Bergeron A; Bourdin A; Bouvaist H; Canuet M; Pison C; Macro M; Poubeau P; Girerd B; Natali D; Guignabert C; Perros F; O'Callaghan DS; Jaïs X; Tubert-Bitter P; Zalcman G; Sitbon O; Simonneau G; Humbert M
Circulation; 2012 May; 125(17):2128-37. PubMed ID: 22451584
[TBL] [Abstract][Full Text] [Related]
15. [Treatment with imatinib for refractory PAH].
Nakamura K; Akagi S; Sarashina T; Ogawa A; Matsubara H; Ito H
Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):173-7. PubMed ID: 24717604
[No Abstract] [Full Text] [Related]
16. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.
Sano M; Saotome M; Urushida T; Katoh H; Satoh H; Ohnishi K; Hayashi H
Intern Med; 2012; 51(17):2337-40. PubMed ID: 22975544
[TBL] [Abstract][Full Text] [Related]
18. PDGF receptor and its antagonists: role in treatment of PAH.
Grimminger F; Schermuly RT
Adv Exp Med Biol; 2010; 661():435-46. PubMed ID: 20204747
[TBL] [Abstract][Full Text] [Related]
19. Eicosapentaenoic acid ameliorates pulmonary hypertension via inhibition of tyrosine kinase Fyn.
Kurahara LH; Hiraishi K; Yamamura A; Zhang Y; Abe K; Yahiro E; Aoki M; Koga K; Yokomise H; Go T; Ishikawa K; Bo Z; Kishi H; Kobayashi S; Aoki-Shoi N; Toru S; Inoue R; Hirano K
J Mol Cell Cardiol; 2020 Nov; 148():50-62. PubMed ID: 32889002
[TBL] [Abstract][Full Text] [Related]
20. [Clinical use of tyrosine kinase inhibitors for treatment of myeloid leukemias].
Tojo A
Nihon Rinsho; 2009 Oct; 67(10):1926-31. PubMed ID: 19860192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
